Latest news
Investment in formulation development
Iconovo has raised 2.3 million EUR to expand the in-house development capacity. We will now be able to offer a comprehensive product development including…
Dry Powder Inhalers in London
Iconovo CEO Dr. Orest Lastow will be giving a speach at Dry Powder Inhalers Conference 27-28 July in London. The title of the speach is "How to develop…
Press releases
Feb 08, 2023, 17:32
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 08, 2023, 17:31
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:31
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 03, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 03, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Jan 11, 2023, 08:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
